Research funder · United States
Melanoma Research Alliance
Nonprofit organization in Washington D.C., United States
- Grants since 2016
- 400
- Awarded, last 5 years (where amounts are published)
- 72.1M
- Funded works, last 5 years
- 1 190
- Funded works, all time
- 2 826
Grants
2020–2023 · award
Overcoming upfront resistance to neoadjuvant CTLA-4 plus PD-1 blockade
Christian Blank
2020–2023 · award
Targeting persister cell states that drive drug resistance and metastasis
Richard White
2020–2023 · award
Activating dsRNA sensing in melanoma to overcome immunotherapy resistance
Jeffrey Ishizuka
2020–2022 · award
Tandem cytokine delivery with non-replicating herpes viral vectors
Stephanie Dougan
2020–2021 · award
Multimedia Learning for Melanoma Prevention and Early Detection Education
Carter Haag
2020–2021 · award
A novel integrin-dependent metastasis pathway in melanoma
Mariana Silva
2020–2023 · award
Germline biomarkers of melanoma immunotherapy: an international consortium
Tomas Kirchhoff
2020–2023 · award
Targeting interactions between melanoma metabolism and radiation therapy
Aparna Kesarwala
2020–2023 · award
Identification of Druggable Transcriptional Drivers in Melanoma
Liron Bar-Peled
2020–2021 · award
Melanoma Staging by Artificial Intelligence
Enrica Quattrocchi
2020–2023 · award
Microenvironmental Regulators of Melanoma Brain Metastases
Berta Lopez Sanchez-Laorden
2020–2022 · award
Histone variant regulation of the melanoma microenvironment
Emily Bernstein
2020–2024 · award
Investigating melanoma metastases
Samra Turajlic
2020–2023 · award
The effects of age on tumor dormancy
Ashani Weeraratna
2020–2023 · award
AI-Augmented Melanoma Triage and Diagnosis : A Prospective Multi-Site Study
Roberto Novoa
2020–2022 · award
Role of Amyloid beta in Brain Metastasis
Eva Hernando
2020–2023 · award
Examining the role of blebs in melanoma metastasis
Jeremy Logue
2020–2021 · award
Transcriptional profiling and marker identification of early stage melanoma
Qi Sun
2020–2021 · award
Early Detection and Novel Therapies Impact Melanoma Incidence and Mortality
Juliana Berk-Krauss
2020–2023 · award
Evolution of metabolic and immune dysfunction in in-transit melanoma
Greg Delgoffe
2020–2021 · award
Mechanisms and Treatments of Metastatic Dissemination by Stage III Melanoma
Sixue Liu
2020–2021 · award
Characterizing the genomic evolution of acral lentiginous melanoma
Meng Wang
2020–2023 · award
Mechanisms of organ-specific cutaneous and uveal melanoma metastases
Roger Lo
2020–2022 · award
Targeting immune inhibitory gene transcription to reverse T cell exhaustion
Linda Bradley
2020–2023 · award
Predictors of response to neoadjuvant therapy in melanoma
Rodabe Amaria
2020–2021 · award
Preventing melanomagenesis through modulating HMGB1 palmitoylation
Zhipeng Tao
2019–2021 · award
Development of Novel YAP-TEAD Inhibitors for Uveal Melanoma
Fernando Camargo
2019–2021 · award
Exploring differential PARP1 expression for non-invasive melanoma diagnosis
Aditi Sahu
2019–2022 · award
Dissecting tumor-immune cell interactions in uveal melanoma
Ashley Laughney
2019–2022 · award
Targeting MAPK and PI3K signaling via CK2 inhibition in acral melanoma
Angela Christiano
2019–2022 · award
Finding Pathways That Drive T-Cells Into Melanoma
Leonard Zon
2019–2021 · award
Differentiating Change Over Time In Melanoma As Compared To Benign Nevi
Marry Smith
2019–2021 · award
Targeting ferroptosis to combat resistant forms of melanoma
James Olzmann
2019–2020 · award
Transcriptional profiling and marker identification of early stage melanoma
Qi Sun
2019–2021 · award
Determining the Immune Inhibitory Landscape in Melanoma
Matthew Vesely
2019–2022 · award
Investigating Host Immune Factors in Mediating Immune Related Adverse Event
Shaheen Khan
2019–2022 · award
Eradicating melanoma drug-tolerant cells
Jean-Christophe Marine
2019–2022 · award
Studying the effects of intra-tumor heterogeneity on anti-tumor immunity
Yardena Samuels
2019–2022 · award
Microbial metabolites in immunotherapy of malignant melanoma
Simon Heidegger
2019–2022 · award
Identifying new molecular targets and drugs to treat resistant Melanoma
Nir London